From a clinical, morphological and molecular perspective, prostate cancer is a
heterogeneous disease. Primary prostate cancers are often multifocal, having …

This review focuses on histopathological aspects of carcinoma of the prostate. A tissue
diagnosis of adenocarcinoma is often essential for establishing a diagnosis of prostate …

An increasingly recognized resistance mechanism to androgen receptor (AR)-directed
therapy in prostate cancer involves epithelial plasticity, in which tumor cells demonstrate low …

Prostate cancer is the second most common cancer in men worldwide and causes over
250,000 deaths each year. Overtreatment of indolent disease also results in significant …

Recurrent fusions of ETS genes are considered driving mutations in a diverse array of
cancers, including Ewing's sarcoma, acute myeloid leukemia, and prostate cancer. We …

Background: Whether the genomic rearrangement transmembrane protease, serine 2
(TMPRSS2): v-ets erythroblastosis virus E26 oncogene homolog (ERG) has prognostic …

More than 1,000,000 men undergo prostate biopsy each year in the United States, most for
“elevated” serum prostate-specific antigen (PSA). Given the lack of specificity and unclear …

ERG, an ETS family transcription factor, is known to be expressed in endothelial cells, and
oncogenic ERG gene fusions occur in subsets of prostatic carcinoma, acute myeloid …

Prostate cancer is a common heterogeneous disease, and most patients diagnosed in the
post prostate-specific antigen (PSA) era present with clinically localized disease, the …

The ERG gene is fused to TMPRSS2 in approximately 50% of prostate cancers (PrCa),
resulting in its overexpression. However, whether this is the sole mechanism underlying …